BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35335347)

  • 1. In Silico Structure-Based Approach for Group Efficiency Estimation in Fragment-Based Drug Design Using Evaluation of Fragment Contributions.
    Shulga DA; Ivanov NN; Palyulin VA
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In-silico approaches for fragment-based drug design].
    Takahashi O; Masuda Y; Muroya A; Furuya T
    Yakugaku Zasshi; 2010 Mar; 130(3):349-54. PubMed ID: 20190520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment databases from screened ligands for drug discovery (FDSL-DD).
    Wilson J; Sokhansanj BA; Chong WC; Chandraghatgi R; Rosen GL; Ji HF
    J Mol Graph Model; 2024 Mar; 127():108669. PubMed ID: 38011826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment informatics and computational fragment-based drug design: an overview and update.
    Sheng C; Zhang W
    Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fragment-based drug discovery: concept and aim].
    Tanaka D
    Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using DNA-encoded libraries of fragments for hit discovery of challenging therapeutic targets.
    Zhao G; Zhu M; Li Y; Zhang G; Li Y
    Expert Opin Drug Discov; 2024 Jun; 19(6):725-740. PubMed ID: 38753553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post processing of protein-compound docking for fragment-based drug discovery (FBDD): in-silico structure-based drug screening and ligand-binding pose prediction.
    Fukunishi Y
    Curr Top Med Chem; 2010; 10(6):680-94. PubMed ID: 20337587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B; Kang D; Zhan P; Liu X
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery.
    Yamaotsu N; Hirono S
    J Comput Aided Mol Des; 2018 Nov; 32(11):1229-1245. PubMed ID: 30196523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    de Souza Neto LR; Moreira-Filho JT; Neves BJ; Maidana RLBR; GuimarĂ£es ACR; Furnham N; Andrade CH; Silva FP
    Front Chem; 2020; 8():93. PubMed ID: 32133344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site Identification by Ligand Competitive Saturation (SILCS) simulations for fragment-based drug design.
    Faller CE; Raman EP; MacKerell AD; Guvench O
    Methods Mol Biol; 2015; 1289():75-87. PubMed ID: 25709034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of molecular simulations in fragment-based drug design (FBDD): an overview.
    Bissaro M; Sturlese M; Moro S
    Drug Discov Today; 2020 Sep; 25(9):1693-1701. PubMed ID: 32592867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACFIS: a web server for fragment-based drug discovery.
    Hao GF; Jiang W; Ye YN; Wu FX; Zhu XL; Guo FB; Yang GF
    Nucleic Acids Res; 2016 Jul; 44(W1):W550-6. PubMed ID: 27150808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.